| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.86B | 1.84B | 1.95B | 1.94B | 1.76B | 1.42B |
| Gross Profit | 670.05M | 686.03M | 705.64M | 612.65M | 594.64M | 513.44M |
| EBITDA | 129.49M | 284.95M | 290.11M | 239.42M | 253.22M | 138.74M |
| Net Income | -9.00M | 116.64M | 112.75M | -17.81M | 121.37M | 39.66M |
Balance Sheet | ||||||
| Total Assets | 2.82B | 2.61B | 2.71B | 2.82B | 2.96B | 2.89B |
| Cash, Cash Equivalents and Short-Term Investments | 172.04M | 188.88M | 194.53M | 180.96M | 165.18M | 181.83M |
| Total Debt | 897.11M | 737.82M | 788.97M | 979.77M | 919.68M | 915.11M |
| Total Liabilities | 1.45B | 1.26B | 1.33B | 1.54B | 1.57B | 1.57B |
| Stockholders Equity | 1.36B | 1.35B | 1.38B | 1.28B | 1.39B | 1.32B |
Cash Flow | ||||||
| Free Cash Flow | 127.53M | 215.86M | 240.22M | 13.26M | 27.48M | 160.49M |
| Operating Cash Flow | 152.97M | 204.58M | 279.02M | 41.79M | 48.93M | 178.39M |
| Investing Cash Flow | -213.60M | -76.42M | -27.62M | -40.19M | -49.13M | -71.39M |
| Financing Cash Flow | 23.61M | -122.66M | -238.61M | 24.67M | -13.46M | -75.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $2.63B | 29.05 | 36.39% | 1.93% | 4.98% | 30.84% | |
| ― | $1.75B | -2,107.52 | -0.09% | 0.79% | -2.53% | -100.23% | |
| ― | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
| ― | $2.31B | ― | -0.64% | 1.41% | 0.08% | -107.33% | |
| ― | $1.83B | 97.68 | 1.55% | 2.22% | -5.45% | -87.13% | |
| ― | $1.96B | ― | -106.83% | ― | -14.45% | 49.92% | |
| ― | $2.20B | -2.59 | -34.43% | 3.40% | -11.38% | -690.99% |
Quaker Chemical faces a potential business risk related to insider trading arrangements and policies. As of the quarter ending September 30, 2025, no directors or officers of the company have adopted or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements. This lack of activity could raise concerns about the company’s internal controls and governance practices, potentially affecting investor confidence. Stakeholders may scrutinize the company’s adherence to regulatory compliance and its ability to manage insider trading risks effectively.